Literature DB >> 9458940

Dexamethasone for pulmonary interstitial emphysema in preterm infants.

D Fitzgerald1, D Willis, R Usher, E Outerbridge, G M Davis.   

Abstract

The efficacy of a 3-day course of dexamethasone (0.5 mg/kg/ day) in 10 preterm infants (< or = 30 weeks gestation) with pulmonary interstitial emphysema (PIE) was studied in a retrospective case review. PIE was diagnosed at a median age of 7.5 days and treatment with dexamethasone began at 8.5 days. Seven of the 10 subjects had at least 2 days of conservative treatment (lowered mean airway pressure) preceding dexamethasone during which the mean airway pressure (MAP), oxygenation index (OI) and mechanical ventilation index (MVI) were not significantly different although within 3 days of dexamethasone each variable improved significantly (p < 0.05). Similarly, for all 10 infants, OI and MAP were significantly lower at 3 and 7 days from baseline (p < 0.005). By day 7, FiO2 (p = 0.022) and MVI (p = 0.011) were significantly lower and PIE had resolved on chest X-ray in 7/9 (78%) and improved in the remaining 2/9 (22%). Nine of the 10 infants survived to term. Three days of dexamethasone was associated with significant clinical improvement in most of these infants. The mechanism may relate to reduced airway oedema and inflammation and reduced airway obstruction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9458940     DOI: 10.1159/000013957

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  2 in total

1.  Percutaneous evacuation of diffuse pulmonary interstitial emphysema by lung puncture in a baby with extremely low birth weight: a case report.

Authors:  Masahiro Watanabe; Nobuo Momoi; Maki Sato; Hayato Go; Takashi Imamura; Masatoshi Kaneko; Mitsuaki Hosoya
Journal:  J Med Case Rep       Date:  2012-09-26

2.  A Case of Pulmonary Interstitial Emphysema Treated by Percutaneous Catheter Insertion in Extremely Low Birth Weight Infant.

Authors:  Changsin Kim; Jeong Eun Shin; Soon Min Lee; Ho Seon Eun; Min Soo Park; Kook In Park; Ran Namgung; Sungsoo Lee; Choon Sik Yoon
Journal:  Yonsei Med J       Date:  2016-11       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.